| Literature DB >> 24663060 |
Yahia N Mabkhot1, Abdullah M Al-Majid2, Assem Barakat3, Salim S Al-Showiman4, Munirah S Al-Har5, Smaail Radi6, Muhammad Moazzam Naseer7, Taibi B Hadda8.
Abstract
A series of new 2-aminobenzamide derivatives (1-10) has been synthesized in good to excellent yields by adopting both conventional and/or a time-efficient microwave assisted methodologies starting from isatoic anhydride (ISA) and characterized on the basis of their physical, spectral and microanalytical data. Selected compounds of this series were then tested against various bacterial (Bacillus subtilis (RCMB 000107) and Staphylococcus aureus (RCMB 000106). Pseudomonas aeruginosa (RCMB 000102) and Escherichia coli (RCMB 000103) and fungal strains (Saccharomyces cerevisiae (RCMB 006002), Aspergillus fumigatus (RCMB 002003) and Candida albicans (RCMB 005002) to explore their potential as antimicrobial agents. Compound 5 was found to be the most active compound among those tested, which showed excellent antifungal activity against Aspergillus fumigatus (RCMB 002003) more potent than standard Clotrimazole, and moderate to good antibacterial and antifungal activity against most of the other strains of bacteria and fungi. Furthermore, potential pharmacophore sites were identified and their activity was related with the structures in the solution.Entities:
Mesh:
Substances:
Year: 2014 PMID: 24663060 PMCID: PMC3975443 DOI: 10.3390/ijms15035115
Source DB: PubMed Journal: Int J Mol Sci ISSN: 1422-0067 Impact factor: 5.923
Scheme 1.Synthesis of 2-aminobenzamide derivatives (1–10) from isatoic anhydride (i): R-NH2 in heating dimethylformamide (DMF).
Antimicrobial activity (inhibition zones in mm) of some of compounds 1–10 [e].
| Compound | Bacteria | Fungi | |||||
|---|---|---|---|---|---|---|---|
|
|
| ||||||
| (A) | (B) | (C) | (D) | (E) | (F) | (G) | |
| 9.9 | 9.7 | 9.1 | 9.4 | 11.8 | 11.2 | 11.9 | |
| 7.2 | 7.8 | 7.4 | 6.9 | 9.4 | 8.2 | 8.4 | |
| 11.9 | 11.1 | 10.4 | 9.5 | 11.8 | 11.5 | 11.2 | |
| 17.9 | 19.2 | 10.9 | 12.4 | 19.7 | 20.1 | 15.8 | |
| 9.1 | 8.8 | 7.9 | 7.6 | 12.2 | 9.4 | 7.2 | |
| - | - | - | - | 18.3 | 23.1 | 26.1 | |
| 25.1 | 30.1 | 25.6 | 24.3 | - | - | - | |
(A): Staphylococcus aureus (RCMB 000106); (B): Bacillis subtilis (RCMB 000107); (C): Pseudomonas aeruginosa (RCMB 000102); (D): Escherichia coli (RCMB 000103); (E): Aspergillus fumigatus (RCMB 002003); (F): Saccharomyces cerevislae (RCMB 006002); (G): Candida albicans (RCMB 005002);
Antibacterial Gram-positive;
Antibacterial Gram-negative;
CLOZO: Clotrimazole (St. 25 μL/mL);
STREPT; Streptomycin (St. 25 μL/mL);
Mean zone of inhibition in mm ± standard deviation beyond well diameter (6 mm) produced on a range of environmental and clinically pathogenic microorganism using (5 mg/mL) concentration of tested samples.
Figure 1.The structural parameters do not indicate a tautomeric equilibrium but a single amino/amido form. The main differences between the two crystalline forms lie in the intramolecular hydrogen of NH2 bonding and its relative orientation to oxygen of amide [28]. Attractive intramolecular interactions occur and are responsible for the closure of pharmacophore site (C=Oδ−–NH2 δ+).
Figure 2.Impact of tautmerism on opening/closing antimicrobial pharmacophore site of 1–10.